Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

Fig. 2

Progression-free survival (PFS, a) and overall survival (OS, b) of low and other than low (low-, high-intermediate, and high) risk patients by IPI treated either with (N = 32 and N = 13) or without (N = 18 and N = 13) rituximab. IPI was not available in 4 patients in the no rituximab treatment group. These patients were excluded from the survival analyses. Median PFS and OS not reached. Due to multiple testing (k = 2) a P-value <0.025 is considered as statistically significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us